arGEN-X opens new R&D facility in Flanders
arGEN-X BV announced that it has opened a new R&D subsidiary in Flanders – arGEN-X BVBA. The facility is supported by a €1.3 million grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) and is intended to become a center of excellence dedicated to the discovery and development of novel therapeutic antibodies based on arGEN-X’ SIMPLE Antibody™ platform.
The facility will operate under arGEN-X’ CSO Prof. Dr. Hans de Haard, and CDO Dr. Torsten Dreier, who have already attracted an experienced international core team of antibody discovery and development as well as project management experts. Among those recently appointed is Dr Michael Saunders, who has joined arGEN-X as Senior Director Targets & Programs, bringing important relevant experience from within GlaxoSmithKline in target identification and project management. Under this leadership, the Company is in the process of building an international team of around 25 antibody scientists to be based at this facility.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
OncoMed Pharmaceuticals and Fluidigm annouce strategic collaboration
Reactive_airway_disease
Acidophile_(histology)

New gene expression mechanism with possible role in human disease
BIOTECHNICA 2010 with new focus topics

New technology for enzyme design

Intuition and failure as valuable ingredients in chemical research - Methodology to collect lessons learned from partially failed trials and incorrect hypotheses
